Free radical-mediated alkylation of general alkenes is a challenging and largely unmet goal. Herein, we disclose a conceptually novel "polarity umpolung" strategy for radical alkylation of alkenes using a portfolio of easily-accessed, dual-function alkylating reagents. This is achieved by substituting inherently nucleophilic alkyl radicals with electrophilic sulfone-decorated surrogates, thus inverting
1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as ptp-as inhibitors
申请人:Barnes David
公开号:US20100035942A1
公开(公告)日:2010-02-11
Compounds of the formula
are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibitors of other enzymes characterized with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds of formula (I) may be employed for prevention and/or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels, conditions that accompany type-2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated. In addition, the compounds of the present invention may be employed to treat and/or prevent cancer, osteoporosis, neurodegenerative and infectious diseases, and diseases involving inflammation and the immune system.
1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as PTP-as inhibitors
申请人:Novartis AG
公开号:US08252820B2
公开(公告)日:2012-08-28
Compounds of the formula
are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibitors of other enzymes characterized with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds of formula (I) may be employed for prevention and/or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels, conditions that accompany type-2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated. In addition, the compounds of the present invention may be employed to treat and/or prevent cancer, osteoporosis, neurodegenerative and infectious diseases, and diseases involving inflammation and the immune system.
producing a library of functionalized trifluoromethylated δ,ϵ- or γ,δ-unsaturatedaldehydes in moderate to excellent yields with good functional group tolerance. The controllable installation of three functional groups, such as CF3, CHO, and a C−C double bond, provides a very attractive protocol for rapid synthesis of complex molecules from simple starting materials.